Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.

Enlivex ( ($ENLV) ) has issued an update. On April 8, 2026, Enlivex announced that Ondo Finance has launched ENLVon, a tokenized representation of ...

Enlivex Shares Tokenized on Ondo Global Markets to Expand Global Digital Investor Access

The latest announcement is out from Enlivex ( ($ENLV) ). Enlivex Ltd., a quality longevity company listed on Nasdaq and headquartered in Nes‑Ziona,...

Enlivex Posts $1.23 Billion Profit for 2025 on Treasury Asset Gains

Enlivex ( ($ENLV) ) has provided an announcement. On March 23, 2026, Enlivex completed a $21 million senior secured convertible note financing with...

Enlivex Secures $21 Million Convertible Debt, Expands RAIN Token Holdings and Launches $20 Million Buyback

The latest update is out from Enlivex ( ($ENLV) ). On March 23, 2026, Enlivex announced that the U.S. Food and Drug Administration cleared its Inve...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ENLV	$0.93	+11.11%	1.43M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ENLV	$0.93	+11.1%	1.43M
3
4
5
6

ENLV

ENLV

Get Enlivex Therapeutics Ltd. Data in Excel

Get Enlivex Therapeutics Ltd. Data in Excel